Dimerix Limited (ASX:DXB)

Market Cap	111.07M -65.7%
Revenue (ttm)	7.42M +1,219.9%
Net Income	-16.31M
EPS	-0.03
Shares Out	600.40M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,345,455
Open	0.1800
Previous Close	0.1750
Day's Range	0.1800 - 0.1900
52-Week Range	0.1750 - 0.6650
Beta	0.40
Analysts	n/a
Price Target	n/a
Earnings Date	Jun 2, 2026

About Dimerix

Dimerix Limited, a biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs in Australia. It develops DMX-200 for the treatment of focal segmental glomerulosclerosis disease, diabetic kidney disease, and ARDS associated with COVID-19; and DMX-700 for orphan respiratory/renal disease, as well as proprietary Receptor-HIT assay technology. The company is headquartered in Fitzroy, Australia.

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Nina Webster
• Employees: 15
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: DXB

Financial Performance

In fiscal year 2025, Dimerix's revenue was 5.59 million, an increase of 1271.12% compared to the previous year's 407,466. Losses were -13.25 million, -22.39% less than in 2024.